Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02855944 · OUTCOME

Overall Survival (ITT Population)

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients · Source last updated 2023-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
All patients were followed for survival up to approximately 3.5 years.

What was measured

Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.

Analysis population: Intent-to-Treat (ITT) Population - All randomized patients in the treatment part of the study.

Groups in this outcome

Rucaparib

Patients randomized to the rucaparib arm.

Chemotherapy

Patients randomized to the chemotherapy arm.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rucaparib233
Chemotherapy116

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Rucaparib19.4Not reported15.223.6Not reported
Chemotherapy25.4Not reported21.427.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        15.2
        upper Limit
        23.6
        value
        19.4
      2. group Id
        OG001
        lower Limit
        21.4
        upper Limit
        27.6
        value
        25.4
denoms
  1. counts
    1. group Id
      OG000
      value
      233
    2. group Id
      OG001
      value
      116
    units
    Participants
description
Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients randomized to the rucaparib arm.
    id
    OG000
    title
    Rucaparib
  2. description
    Patients randomized to the chemotherapy arm.
    id
    OG001
    title
    Chemotherapy
param Type
MEDIAN
population Description
Intent-to-Treat (ITT) Population - All randomized patients in the treatment part of the study.
reporting Status
POSTED
time Frame
All patients were followed for survival up to approximately 3.5 years.
title
Overall Survival (ITT Population)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice